<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01276990</url>
  </required_header>
  <id_info>
    <org_study_id>1277.2</org_study_id>
    <nct_id>NCT01276990</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 in Healthy Male Volunteers.</brief_title>
  <official_title>Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 ZW (Powder in Bottle Formulation) at 12.5 mg q24h, 12.5 mg q12h, 12.5 mg q8h, 25 mg q12h, 25 mg q8h, 50 mg q12h, 37.5 mg q8h and 50 mg q8h Dose Levels for 10 Days in Healthy Male Volunteers (Randomized, Double-blind Placebo-controlled Within Dose Groups)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate the safety and pharmacokinetic of BI 224436 in healthy male volunteers
      following oral administration of repeated doses for 10 days within 8 dosing regimens.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2011</start_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in blood pressure</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in pulse rate</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in 12-lead ECG</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in clinical laboratory test parameters</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss (maximum measured concentration of the analyte in plasma at steady-state over a uniform dosing interval t)</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady-state)</measure>
    <time_frame>10 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss (minimum concentration of the analyte in plasma at steady-state over a uniform dosing interval t)</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady-state over a uniform dosing interval t)</measure>
    <time_frame>13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2,ss (terminal half-life of the analyte in plasma at steady-state)</measure>
    <time_frame>13 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F,ss (apparent clearance of the analyte in the plasma at steady-state following extravascular multiple dose administration)</measure>
    <time_frame>13 days</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>HIV Infections</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo in dosing regimen 1-8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 224436 dosing regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing regimen 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 224436 dosing regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing regimen 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 224436 dosing regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing regimen 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 224436 dosing regimen 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing regimen 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 224436 dosing regimen 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing regimen 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 224436 dosing regimen 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing regimen 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 224436 dosing regimen 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing regimen 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 224436 dosing regimen 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing regimen 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 224436</intervention_name>
    <description>Oral drinking solution</description>
    <arm_group_label>BI 224436 dosing regimen 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 224436</intervention_name>
    <description>Oral drinking solution</description>
    <arm_group_label>BI 224436 dosing regimen 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 224436</intervention_name>
    <description>Oral drinking solution</description>
    <arm_group_label>BI 224436 dosing regimen 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 224436</intervention_name>
    <description>Oral drinking solution</description>
    <arm_group_label>BI 224436 dosing regimen 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 224436</intervention_name>
    <description>Oral drinking solution</description>
    <arm_group_label>BI 224436 dosing regimen 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 224436</intervention_name>
    <description>Oral drinking solution</description>
    <arm_group_label>BI 224436 dosing regimen 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 224436</intervention_name>
    <description>Oral drinking solution</description>
    <arm_group_label>BI 224436 dosing regimen 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 224436</intervention_name>
    <description>Oral drinking solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 224436</intervention_name>
    <description>Oral drinking solution</description>
    <arm_group_label>BI 224436 dosing regimen 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral drinking solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy male according to the following criteria: based upon a complete medical
             history, including the physical examination, vital signs (Blood Pressure (BP), Pulse
             Rate (PR)), 12-lead Electrocardiogram (ECG), clinical laboratory tests.

          2. Age &gt;=18 and &lt;=50 years.

          3. Body Mass Index (BMI) &gt;=18.5 and BMI &lt;=32 kg/m2.

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice and the local legislation.

          5. Documented to be sterile; or, if can father a child, agree to abstain from sexual
             intercourse during and at least seven days following last study drug administration,
             or are willing to use condoms during the same period each time (Subject's female
             sexual partner(s) of child-bearing potential should be willing to use either ethinyl
             estradiol containing oral contraceptives or a reliable barrier method of
             contraception).

        Exclusion criteria:

          1. Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal and of clinical relevance according to the opinion of the investigator.

          2. Any evidence of a clinically relevant concomitant disease.

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders.

          4. Surgery of the gastrointestinal tract that in the opinion of the investigator may
             affect the absorption.

          5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders.

          6. History of relevant orthostatic hypotension, fainting spells or blackouts.

          7. History or evidence of Human Immunodeficiency Virus or other chronic or relevant acute
             infections, including Hepatitis C Virus and Hepatitis B Virus infection.

          8. History of relevant allergy / hypersensitivity (including allergy to investigational
             medicinal product or its solvent).

          9. History of any familial skeletal muscle disorder, or history of Creatine Kinase (CK)
             elevation not due to strenuous physical activity or trauma.

         10. Intake of drugs with a long half-life (&gt;24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial.

         11. Use of drugs, including prescription and non-prescription drugs, and St. Johns Wort
             which might reasonably influence the results of the trial within 14 days prior to
             study drug administration or during the trial, or consumption of grapefruit,
             grapefruit juice, orange juice, Seville oranges, green tea, pineapple, pineapple
             juice, broccoli or red wine within 3 days prior study drug administration or during
             the trial.

         12. Participation in another trial with an investigational drug within one month prior to
             administration or during the trial.

         13. Current smoker (&gt;10 cigarettes or &gt;3 cigars or &gt;3 pipes / day).

         14. Inability to refrain from smoking during the trial.

         15. Alcohol abuse (more than 30 g day).

         16. Drug abuse.

         17. Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial).

         18. Physical activity in excess of usual activity of daily living (e.g., fitness physical
             exercise, physical labor) within 7 days prior to study drug administration until end
             of study visit.

         19. Any laboratory value outside the reference range that in the opinion of the
             investigator is of clinical relevance.

         20. A marked baseline prolongation of QT or corrected QT (QTc) intervals (e.g., repeated
             demonstration of a QTc interval &gt;450 ms); or, other ECG abnormality of clinical
             significance.

         21. A history of additional risk factors for Torsades de points (e.g., heart failure,
             hypokalemia, family history of Long QT Syndrome).

         22. CK at screening =2x Upper Limit of Normal (ULN) (If CK is =2xULN and &lt;5xULN one retest
             will be allowed to verify the result).

         23. CK at baseline (Day -1) &gt;ULN (If CK is &gt;ULN and &lt;1.5xULN one retest will be allowed to
             verify the result).

         24. Thyroid - stimulating hormone outside normal reference range, or history of hypo-or
             hyperthyroidism.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2011</study_first_submitted>
  <study_first_submitted_qc>January 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2011</study_first_posted>
  <last_update_submitted>February 8, 2012</last_update_submitted>
  <last_update_submitted_qc>February 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

